Refractive targets and visual outcomes in patients implanted with extended-depth-of-focus IOLs after cataract surgery

Session Details

Session Title: Extended-Depth-Of-Focus IOLs II

Session Date/Time: Monday 16/09/2019 | 14:00-16:00

Paper Time: 15:36

Venue: Free Paper Forum: Podium 1

First Author: : M.Jackson USA

Co Author(s): :    A. Edmiston                             

Abstract Details

Purpose:

To evaluate visual acuity, refraction, and efficacy of refractive targeting in patients implanted with toric extended depth of focus (EDOF) IOLs.

Setting:

Jacksoneye, Lake Villa, IL Lindenhurst Ambulatory Surgery Center, Lindenhurst, IL

Methods:

Patients who had undergone cataract surgery in both eyes and were implanted with a Symfony toric EDOF IOL in at least one eye were examined between 3 months and 1 year postoperatively. Manifest refraction spherical equivalent (MRSE), residual astigmatism, eye dominance, and uncorrected visual acuity (LogMAR scale) at distance, intermediate, and near (UDVA, UIVA, UNVA) were recorded. Postoperative refractive astigmatism was compared to preoperative corneal astigmatism. MRSE was plotted against UDVA, UIVA, and UNVA to determine the ideal refractive target for both dominant and nondominant eyes.

Results:

94 eyes of 47 patients were implanted with Symfony toric lenses were evaluated for the purposes of refractive targeting. Postoperative MRSE was -0.08 ± 0.41 D, and 84.04% of eyes had a postop MRSE within ± 0.5 D of plano. 92.47% of eyes had ≤0.75 D of residual cylinder. Postop refractive astigmatism was 0.33 ± 0.39 D, compared to 1.54 D preop (p<0.001). Postop UDVA was 0.03 ± 0.09 D (LogMAR), and 95.74% of eyes had UDVA of 20/25 or better. 85.11% of eyes had UIVA of 20/20 or better. 53.19% eyes had UNVA of J2 or better.

Conclusions:

Patients implanted with Symfony toric IOLs achieved excellent uncorrected visual acuity, with minimal residual astigmatism three months after surgery. In general, a refractive target for MRSE "near plano" produced the best uncorrected visual acuity results, specifically -0.07 ± 0.14 in dominant eyes and -0.21 ± 0.24 in nondominant eyes.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented